Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 09 Sept 2025, 04:05 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]](https://i.ytimg.com/vi/4VxxDgfNcB8/hqdefault.jpg)
AI-generated source summary
The analysis assesses Rapport Therapeutics, indicating several positive signals, but overall concludes that the stock is not currently a buy but to hold. The price target for the next trading day is at $33.60, and has a stop-loss recommendation is set at $30.41, has high volatility but medium risk. Recent news indicates promising phase 2a trial results and underwritten public offering. Analyst ratings lean towards a sell consensus with negative price-to-earnings and price-to-book ratios and insider trades indicate slightly positive signals. There are buy signals from both short and long-term moving averages, yet with downside volume and some analyst sell recommendations; however system indicators show the stock price as currently undervalued.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.